We sought to report on laboratory and clinical experience following 6 months of clinical implementation of a single-nucleotide polymorphismebased noninvasive prenatal aneuploidy test in highand low-risk women.
and lower false-positive (FP) rates than current screening methods. Opinion statements by national and international professional societies support the clinical use of NIPT in pregnant women, with most recommending use restricted to women at high risk for fetal aneuploidy. [15] [16] [17] Two approaches to NIPT have been developed and commercialized. In the first approach, fetal chromosome copy number is determined by comparing the number of sequence reads from the chromosome(s) of interest to those from reference chromosomes. 7, 8, [11] [12] [13] [18] [19] [20] [21] [22] The second approach entails targeted amplification and sequencing of single-nucleotide polymorphisms (SNPs). [2] [3] [4] [5] 23, 24 This approach requires a sophisticated informatics-based method to compute aneuploidy risk through SNP distribution. Validation of the SNP-based NIPT method at 11-13 weeks' gestation was recently reported, demonstrating high sensitivity and specificity for detection of trisomy 21, trisomy 18, trisomy 13, Turner syndrome (monosomy X), and triploidy. 2, 3 Despite hundreds of thousands of tests already having been performed worldwide, there are few large-scale reports describing performance of NIPT in actual clinical settings, 22, 25 with most studies reporting on <1000 total patients. [26] [27] [28] [29] Here, laboratory and clinical experience of >31,000 women who received prenatal screening with a SNPbased NIPT is reported.
MATERIALS AND METHODS
This is a retrospective analysis of prospectively collected data on 31,030 cases received for commercial testing from March through September 2013. This study received a notification of exempt determination from an institutional review board (Albert Einstein College of Medicine Institutional Review Board: no. 2014-3307). Samples were classified as out of specification and excluded in cases of gestational age <9 weeks, multiple gestation, donor egg pregnancy, surrogate carrier, missing patient information, sample received >6 days after collection, insufficient blood volume (<13 mL), wrong collection tube used, or if the sample was damaged.
Analysis was performed for all samples on chromosomes 13, 18, 21, X, and Y, and included detection of trisomy 21, trisomy 18, trisomy 13, and monosomy X. All samples were processed and analyzed at Natera Inc's Clinical Laboratory Improvement Act (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory (San Carlos, CA). Laboratory testing was performed as previously described using validated methodologies for cfDNA isolation, polymerase chain reaction amplification targeting 19, 488 SNPs, high-throughput sequencing, and analysis with the next-generation aneuploidy test using SNPs (NATUS) algorithm. [2] [3] [4] [5] Samples were subject to a stringent set of quality-control metrics. A second blood draw (redraw) was requested if total input cfDNA, fetal cfDNA fraction, or signal-to-noise ratio did not meet quality metrics, or for poor fit of the data to the model. In cases of large regions (>25%) of loss of heterozygosity or suspected maternal or fetal mosaicism, redraw was not requested. Reports included a risk score for the 4 aneuploidies; when requested, reports included fetal sex. Risk scores were calculated by combining the maximum likelihood estimate generated by the NATUS algorithm with maternal and gestational age prior risks. All samples with a risk score !1/100 were reported as high risk for fetal aneuploidy and samples with risk scores <1/100 were considered low risk. For the purposes of this study, the high-risk results were further divided into a maximum-risk score of 99/100 or an intermediate-risk score of !1/100 and <99/100. The presence of >2 fetal haplotypes (indicative of either triploidy or multiple As the follow-up cohort does not include any out-of-specification cases, or any cases that failed to receive a noninvasive prenatal testing result, minimum gestational age and fetal fraction are higher than in the whole cohortehowever, mean values and SD are equivalent between the 2 cohorts; c Analysis of maternal weight was limited to centers and laboratories that provided this information, and samples originating from United States to avoid inconsistent weight units. gestation) was reported only when the confidence was >99.9%. Additional sex chromosome aneuploidies (XXX, XXY, and XYY) were reported from June 2013. The following patient characteristics were requested for each sample: maternal date of birth, maternal weight, gestational age, and whether a paternal sample was included.
Patients with available International Classification of Diseases, Ninth Revision (ICD-9) codes (Appendix; Supplementary Table 1) were categorized into 3 subcohorts: (1) "low risk" if aged <35 years and no aneuploidy-related high-risk codes; (2) "at risk" for fetal aneuploidy based solely on maternal age !35 years; or (3) "high risk" for fetal aneuploidy by ICD-9 code, regardless of maternal age. High-risk indications included positive screening tests, ultrasound anomalies, and relevant family history. Patients without reported ICD-9 codes were categorized by maternal age as low risk (<35 years) or high risk (!35 years).
Follow-up information on high-risk results was obtained by telephone and recorded in an internal database. Clinical follow-up was completed on June 14, 2014 , at which time all pregnancies were completed. Two partner laboratories accounting for 38.1% of the total 31,030 cases were responsible for their own follow-up efforts and were excluded from outcome calculations. Providers were encouraged to share information about false-negative (FN) results. Samples were categorized as follows: (1) "true positive" (TP) included high-risk samples that were confirmed by prenatal or postnatal diagnostic testing, or based on clinical evaluation at birth; (2) "FP" included high-risk samples that were shown to be euploid by follow-up testing or based on clinical evaluation at birth; (3) "suggestive" included samples where prenatal ultrasound detected at least 1 structural anomaly and 1 soft sonographic marker consistent with NIPT findings, but karyotype confirmation was not obtained; (4) "pregnancy loss" where the patient experienced spontaneous abortion and karyotype confirmation was not obtained; (5) "termination" where the patient elected to end the pregnancy without karyotype confirmation; (6) "no follow-up" included samples where information was unavailable; and (7) "FN" included NIPT low-risk samples that were reported as aneuploid by the provider. When placental and fetal karyotypes were both available and determined to be discordant, NIPT findings were considered TP if they matched the fetal karyotype, and FP if they did not match the fetal karyotype. Pregnancies were considered mosaic when chromosome analysis revealed either placental or fetal mosaicism or there was discordance between placental and fetal karyotypes.
Patient and sample characteristics were expressed as means, SD, medians, and ranges. Linear regression analysis was used to determine the relationship between fetal fraction and gestational age, between fetal fraction and maternal weight, and between fetal/maternal cfDNA and maternal weight; a reciprocal model was used when determining the relationship between fetal fraction and gestational age or maternal weight. For comparison of euploid and aneuploid calls, fetal fractions were expressed as multiples of the median (MoM) relative to low-risk calls weighted by week of gestation, and significance determined using a Mann-Whitney rank sum test. The 2 FN results were included in the appropriate aneuploid category, and FP calls were excluded from aneuploidy fetal fraction analyses. The benefit of a paternal sample on redraw rates and differences in aneuploidy incidence between the a priori risk groups were determined using a c 2 test. The Kruskal-Wallis 1-way analysis of variance on ranks test was used to evaluate maternal age and gestational age differences for the different risk groups. Positive predictive value (PPV) ([TP]/ [TP þ FP]) was calculated for cases with known cytogenetic analyses. SigmaPlot 12.5 (Systat Software, San Jose, CA) was used for all statistical analyses. P < .05 was considered statistically significant. (10, 479) in the second trimester. Figure 1 depicts the study flow chart. Samples from 325 (1.0%) patients were excluded as being outside of the Figure 2) ; the most recent first sample redraw rates were 9.4% at 9 weeks' , and 5.4% at !10 weeks' gestation. Around 30% of patients given the opportunity to submit a paternal sample chose to do so, and inclusion of a paternal sample was associated with a lower redraw rate, with a similar decline over the study period ( Figure 2 ). This effect was more pronounced in women weighing >200 lb, where inclusion of a paternal sample reduced the redraw rate from 27.5% to 16.1% (P < .001). The average turn-around time was 9.2 calendar days (95% confidence interval [CI], 9.16e9.23 calendar days), but significant improvements over the study period led to an average turn-around time in the last month of 6.7 calendar days (95% CI, 6.68e6.76 calendar days).
RESULTS

Patients and samples
Fetal fractions
The average fetal fraction was 10.2% (Table 1 ). Regression analysis, using the reciprocal of the independent variable (gestational age or maternal weight), revealed a positive correlation between fetal fraction and gestational age (r 2 ¼ 0.05, P < .001) ( Figure 3 , A), and a negative association between fetal fraction and maternal weight (r 2 ¼ 0.16, P < .001) (Figure 3, B) . Furthermore, with increasing maternal weight, there was an increase in maternal cfDNA (P < .001) and a decrease in fetal cfDNA (P < .001) ( Figure 4 ). Fetal fractions when stratified by aneuploidy were decreased for trisomy 13 (0.759 MoM, P < .001), trisomy 18 (0.919 MoM, P ¼ .012), and monosomy X (0.835 MoM, P < .001), and increased for trisomy 21 (1.048 MoM, P ¼ .018) samples.
NIPT results
The combined rate of high-risk calls for all 4 indications was 1.77% (508/ 28,739); including 324 trisomy 21, 82 trisomy 18, 41 trisomy 13, and 61 monosomy X (Table 2) . One sample was not assigned a risk score for chromosome 21 due to a maternal chromosome 21 partial duplication but was accurately identified as fetal trisomy 21 by the laboratory. Of 20,384 samples evaluated for additional sex chromosome aneuploidies, other than monosomy X, there were 14 (0.07%) identified: 6 XXX, 6 XXY, and 2 XYY. Fetal sex was reported in 24,522 cases. There were no reports of gender discordance from women receiving low-risk reports. For women receiving high-risk reports, confirmation of fetal sex was available for 109 cases, of which 108 (99.1%) were correct; the single discordant case was reported as high-risk for monosomy X (Supplementary Figure) but cytogenetic testing revealed a 46, XY fetus. Although Effect of gestational age and maternal weight on fetal fraction Box plots depicting effects of A, gestational age and B, maternal weight on fetal fraction. Boxes indicate 75th (upper) and 25th (lower) quartiles, solid black line within box indicates median, capped whiskers indicate 90th (upper) and 10th (lower) percentiles, number in each grouping is indicated above 90th percentile whisker. cases with known multiple gestations were excluded, the NATUS algorithm identified 127 (0.4%) samples as having >2 fetal haplotypes, indicative of either unreported twins, vanishing twin, or triploidy.
ICD-9 codes were associated with 19.0% (5468/28,739) of women: 16.6% were low-risk, 44.1% were high-risk based only on advanced maternal age (!35 years), and 39.3% had high-risk codes. As expected, the incidence of aneuploidy calls was smallest in the lowrisk group (0.7%), followed by advanced maternal age women (1.6%), and largest in the high-risk group (3.4%) ( Table 3) . Results for the 23,271 samples without ICD-9 codes showed a similar difference in aneuploidy calls between women aged <35 years (1.0%, 117/ 11,629) and those aged !35 years (2.4%, 274/11,642). From 17, 885 cases in the follow-up cohort, outcome information was sought for the 356 high-risk calls; 152 high-risk calls from the whole cohort described above were not contained within the follow-up cohort.
Follow-up of high-risk calls
Information regarding invasive testing uptake was available for 251/356 (70.5%) cases that received a high-risk result: 39.0% (139) 5 fetal mosaics (TP) were confirmed by amniocentesis (2 trisomy 21, 2 trisomy 18, 1 monosomy X), and 3 cases were considered FP because of confined placental mosaicism (CPM). Two CPM cases were high risk for trisomy 13 and were identified as mosaics by chorionic villus sampling (CVS), one was determined to be euploid by amniocentesis, and the other did not have a follow-up amniocentesis but ultrasound at 20 weeks was read as normal. In the third CPM case, at-birth testing revealed a 100% trisomy 18 placenta and a euploid child. Two FN results (both trisomy 21) were reported to the laboratory following amniocentesis due to other indications.
For the sex chromosome aneuploidies XXX, XXY, and XYY, 7 of the 
Positive predictive value
Based only on cases with cytogenetic diagnosis (Table 4) , the PPV was 90.9% for trisomy 21 and 82.9% for all 4 cytogenetic abnormalities combined (Table 5) . A theoretical PPV was also calculated under the 2 boundary conditions that all unconfirmed high-risk cases were either FP or TP (Table 5) . This provided a range for the PPV of 60-94% for trisomy 21 and 52-89% for all abnormalities combined.
Among women without ICD-9-coded indications, 63 women aged <35 years received high-risk calls, of which 39 (60.9%) had diagnostic testing and 34 were TP, a PPV of 87.2% (95% CI, 72.6e95.7%). Of 176 women !35 years with high-risk calls, 105 (59.7%) had confirmatory karyotyping and 87 were TP, a PPV of 82.9% (95% CI, 74.3e89.5%).
COMMENT
This report of initial clinical experience with this SNP-based NIPT in >31,000 pregnancies demonstrates that performance in clinical settings is consistent with validation studies. [2] [3] [4] [5] Using only cases confirmed through chromosome analysis or clinical evaluation at birth, the PPV in this mixed low-and high-risk population is 90.9% for trisomy 21 and 82.9% for all 4 aneuploidies, which is far better than current screening methods. Even under the highly conservative assumption that all unconfirmed highrisk cases are incorrect, this test still offers improved clinical performance over traditional screening.
The main advantage of this study is the robust information it provides on clinical application of NIPT, which can contribute to, and improve, both test performance and counseling of patients. Fetal fraction, the main variable that affects redraw rates, is positively correlated with gestational age and negatively correlated with maternal weight, agreeing with previous studies. [30] [31] [32] [33] There are 2 main clinical implications from these findings. First, adequate dating will lower the need for redraw, particularly at early gestational ages. Second, inclusion of a paternal blood sample significantly lowers redraw rates and should be offered to patients, particularly those >200 lb. Importantly, cases with extremely low fetal fraction, which typically do not resolve with redraw, may have an increased risk for fetal aneuploidy.
2 This is likely particularly important for maternal triploidy, which is associated with smaller placentas and lower fetal fractions, 2,5 and trisomy 13 and trisomy 18 pregnancies.
In addition to determining the most likely ploidy state of a fetus, the NATUS algorithm also generates a chromosomespecific risk score, which is a measure of the probability of nonmosaic fetal aneuploidy. As expected, data showed that maximum-risk results are more likely to be TP than intermediate-risk results. Although a high-risk score appears to be more indicative of a TP result, individual numerical values should be interpreted cautiously. Regardless of the risk score, confirmatory studies must be offered to all women with positive results without exception. This is particularly important in light of the finding here that 6.2% of women with high-risk results chose to terminate the pregnancy without invasive test confirmation.
Although referred to as fetal cfDNA, the primary source of cfDNA is placental trophoblast cells. 34 CPM, estimated to be present in 1-2% of 10-to 12-week gestations, 35, 36 impacts all NIPTs. Validation studies have typically excluded samples with fetal mosaicism or CPM. Yet, it is clear that when NIPT is performed in a clinical setting, the effect of mosaicism cannot be ignored, and its impact on FP and FN results should be addressed. In this cohort, 8/222 (3.6%) high-risk calls showed evidence of mosaicism. Two cases with CVS results that supported NIPT findings were later categorized as FPs because of CPM. Further, since most FPs in this cohort were determined by amniocentesis or atbirth testing without placental genetic analysis, there may be additional, undetected CPM cases within the FPs. From a retrospective analysis of CVS, Grati et al 37 estimated that the FP rate would be 0.08% for the 4 common aneuploidies. Our findings, combined with the known incidence of CPM-related FPs and FNs, further reinforce the need for adequate pretest counseling, as recommended by American Congress of Obstetrics and Gynecology (ACOG). 17 Patients undergoing CVS following high-risk results with NIPT should be counseled that mosaic conditions can occur and later amniocentesis may be required.
An unexpected finding in this study was that the PPV for women aged <35 Women with ICD-9 codes were sorted into 3 risk populations based on ICD-9 codes and maternal age: low-risk women aged <35 y, women of AMA (aged !35 y) with no other high-risk codes, and high-risk women of any age. Women without ICD-9 codes were sorted into 2 risk populations based on maternal age: low-risk women aged <35 y and high-risk women of AMA.
AMA, advanced maternal age; ICD-9, International Classification of Diseases, Ninth Revision.
a Mean AE SD, there was a significant difference between risk groups (P < .001) for both maternal age and gestational age, as determined by the Kruskal-Wallis 1-way analysis of variance on ranks test; b Trisomy 21 and trisomy 18 totals include single case of double-aneuploidy; c Significant difference in aneuploidy call rate among 3 groups with ICD-9 codes (P < .001), as determined by c 2 test; d Significant difference in aneuploidy call rate between 2 groups without ICD-9 codes (P < .001), as determined by c 2 test. 
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Obstetrics Research years (87%) was similar to that of women aged !35 years (83%). This does not appear to be attributable to a bias in the referral of cases for karyotyping. Some women aged <35 years may have chosen NIPT because of ultrasound findings or positive results with traditional serum screening. However, the lower aneuploidy call incidence of 1.0% in women aged <35 years, vs 2.4% in women aged !35 years (Table 3) , supports that these 2 groups of women do differ substantially with respect to aneuploidy incidence. The PPV was expected to be lower in low-risk women because the number of affected pregnancies would be lower but the number of FPs was predicted to be a constant proportion. 38 The similar PPVs determined in both maternal age groups may indicate that FPs, like affected pregnancies, are also proportionately more common in older women; perhaps arising from trisomic conceptions that are rescued but express CPM. More data are needed to confirm this observation.
Based on the current opinion statement from ACOG, NIPT is appropriate for use in high-risk patients. 17 Nevertheless, the ability to detect aneuploidy with cfDNA depends on assay precision and fetal fraction, not on disease prevalence. Reported PPV in studies performed on mixed high-and low-risk populations, as well as the current study, far exceed current screening methodologies. Consistent with this, recent guidelines published by the American College of Medical Genetics and Genomics (ACMG) do not distinguish between high and low risk. Therefore, the transition of NIPT into a universal, first-line, aneuploidy screen should depend on the availability and affordability of NIPT, and not concerns about performance.
In this cohort of women who were thought to have singleton pregnancies at the time of NIPT, 127 cases were identified as having >2 fetal haplotypes suggesting either triploidy or a previously undetected multifetal pregnancy or vanishing twin. The SNP-based NIPT methodology provided the opportunity to identify these cases, pursue further diagnostic avenues, and avoid FPs that can arise using alternative methodologies. PPV calculated as (TP)/(TP þ FP). Data are presented for just those cases where there was cytogenetic or clinical confirmation of result; based on the extreme condition that all unconfirmed cases were FPs (lower bound) and the opposite condition that all unconfirmed results were TP (upper bound). The main limitation of this study is the incomplete follow-up data, particularly on low-risk patients, precluding precise calculation of sensitivity and specificity. While follow-up was not conducted on low-risk patients, given the clinical significance of a FN report, and based on our laboratory experience, it is likely that FNs would be voluntarily reported; there were 2 voluntarily reported FNs. However, the lack of comprehensive follow-up on all low-risk patients precluded determination of the negative predictive value. Nevertheless, it is important to note that strong performance characteristics were in keeping with prior validation studies, 2, 3, 24 even with the inclusion of mosaic samples. Follow-up of normal results remains an issue for all laboratories that wish to track results for quality assurance, and we support the ACMG recommendation for a national registry. 16 In conclusion, this is a large-scale report of clinical utilization of NIPT. Analysis of >31,000 samples from both low-and high-risk women supported that test performance of this NIPT method in a clinical setting mirrors the robust performance reported in validation studies.
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Clinical performance of SNP-based NIPT in a mixed high-and low-risk population is consistent with performance in validation studies. Similar PPVs were found in women aged <35 years and aged !35 years. The strength of the study is the robust information it provides on clinical application of NIPT. The primary limitation is the incomplete follow-up data, particularly on low-risk patients, precluding precise calculation of sensitivity and specificity.
This study supports the use of NIPT as a first-line screening test for aneuploidy in all patients. Furthermore, it highlights the importance of, as well as provides data that can improve, counseling of patients. Finally, the results of this study raise the questions of how many FP results may be explained by CPM and how best to manage clinical care and diagnostic confirmation of high-risk NIPT results in light of potential CPM. The extent to which CPM may underlie NIPT FP results requires further investigation. where AA is blue, AB is green, and BB is red. When the maternal genotype is homozygous at a specific SNP location (red or blue dots), the presence of single X-chromosome (45,X fetus or XY fetus) can easily be distinguished from 2 X-chromosomes (XX fetus); 45,X fetus with single paternal X-chromosome has a different SNP profile to that shown, but is easily distinguished by the absence of maternal X-chromosome-derived SNPs in the fetus. B, Males are determined by the presence of Y-chromosome SNPs; as fetal fraction increases, Y-chromosome SNPs migrate further away from X-axis, but Y-chromosome SNPs remain detectable down to at least 4% fetal fraction. C, For the single discordant fetal sex case that had a fetal fraction of 10%, SNP data clearly indicate the presence of a single maternal X-chromosome, with no paternal X-chromosome or Y-chromosome detected, leading to the monosomy X result. Mosaicism, which is frequently seen in association with a 45,X cell line, is a possible explanation for this discordant result.
NIPT, noninvasive prenatal testing. 
